Daxor Corp has provided an update on its financial position through a recent filing. As of September 30, 2026, the company reported total assets exceeding $51 million, with liabilities amounting to just $13,771. This financial disclosure is significant as it reflects Daxor's stability in the healthcare industry.

Daxor Corp, listed on the Nasdaq under the ticker DXR, is an operating entity incorporated in New York. The company focuses on the development and commercialization of medical devices, particularly in the field of blood volume measurement. The recent filing, dated November 12, 2026, is categorized as an NPORT-P, which provides insights into the company's financial health.

The filing indicates that Daxor's total net assets stand at approximately $51 million, with a notable portion of its assets invested in U.S. Treasury securities. Specifically, the company holds a U.S. Treasury Bill maturing on January 21, 2027, valued at around $4.83 million. Additionally, Daxor has invested in the UBS Select Government Institutional Fund, further emphasizing its strategy of maintaining liquidity and security in its investments.

According to the filing, Daxor's total liabilities are minimal, with no outstanding amounts due to banks or affiliated companies. This positions the company favorably within the healthcare sector, where financial stability is crucial for ongoing operations and growth. The filing also highlights that Daxor has not reported any unrealized gains or losses in its investments over the past months, indicating a steady performance.

As for the future, the filing does not specify any immediate actions or upcoming events. However, Daxor's focus on maintaining a robust financial position suggests that it may continue to explore opportunities for growth within the healthcare market.